Viatris has reported a 3% year-over-year revenue increase in the first quarter, alongside a 14% rise in adjusted earnings per share, signaling a recovery after years of declining growth. The company's strategic focus on a diversified drug pipeline, including a non-opioid pain reliever and a potential blockbuster lupus treatment, is expected to drive long-term revenue growth.
Viatris is also benefiting from cost-cutting measures that could save $400 million by 2028, contributing to improved margins. The stock has gained over 16% in early May, reflecting investor optimism about its future prospects. Notably, sales in Greater China increased by 18%, highlighting the company's successful adaptation to market demands.
Viatris aims for a compound annual growth rate of 3% to 4% in total revenue through 2030, with expectations of over $2.7 billion in annual free cash flow. The upcoming FDA review of fast-acting meloxicam, expected to peak at $500 million in annual revenue, and the development of cenerimod for lupus treatment are key catalysts that could further enhance the company's growth trajectory.
Analysts view these developments as pivotal for Viatris to transition beyond its generic drugmaker image and capture greater market value